MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
HURA — TuHURA Biosciences, Inc. Common Stock
NasdaqTuHURA Biosciences, Inc. Common Stock
$1.91
-0.07(-3.54%)
- O
- 2.00
- H
- 2.05
- L
- 1.88
- V
- 287.15K
⏱️ End-of-day dataAs of Oct 2, 2026
HURA — Latest News & Headlines
6 StoriesA cancer patent also covers cell-based treatments, not just antibody-linked drugs - Stock Titan
A cancer patent also covers cell-based treatments, not just antibody-linked drugs Stock Titan
Oracle gave Larry Ellison and his co-CEOs nearly $1 billion in stock options. By fiscal year end, all were underwater - Fortune
Oracle gave Larry Ellison and his co-CEOs nearly $1 billion in stock options. By fiscal year end, all were underwater Fortune
Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress - Investing.com UK
Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress Investing.com UK
Oracle (NYSE: ORCL) executive Mark Hura has 8,456 and 20,805 shares withheld for taxes. - Stock Titan
Oracle (NYSE: ORCL) executive Mark Hura has 8,456 and 20,805 shares withheld for taxes. Stock Titan
TuHURA Biosciences receives U.S. patent for DOR technology By Investing.com - Investing.com India
TuHURA Biosciences receives U.S. patent for DOR technology By Investing.com Investing.com India
TuHURA Biosciences Draws Additional Funds From Credit Facility - TipRanks
TuHURA Biosciences Draws Additional Funds From Credit Facility TipRanks